TEK and urinary bladder carcinoma: Our findings offer convincing evidence of Mettl3 in epigenetically modifying TEK/PI3K/VEGF cascades involving in angiogenesis, suggesting that therapeutically targeting Mettl3 may provide one of the alternatives for antiangiogenesis therapy in bladder carcinoma.